CD274 and neoplasm: Accumulating evidence highlight the capacity of anti‐PD‐1/PDL‐1 monoclonal antibodies (mAbs) to target tumor infiltrating lymphocytes (TILs) in situ within tumor beds (Wei et al, 2018).